NGM Biopharmaceuticals, Inc.
Method of treating type I diabetes by administering a combination of a glucagon receptor antagonist and an anti-CD3 antibody
Last updated:
Abstract:
The present disclosure provides methods comprising a glucagon receptor antagonist in combination with an immunotherapeutic agent for treatment of disease.
Status:
Grant
Type:
Utility
Filling date:
26 Jul 2019
Issue date:
30 Mar 2021